SRRA stock: buy or sell?

SRRA stock price: $12.10 6.51% At close on May 15th, 2020

Updated on:
May 15th, 2020

0

Sierra Oncology boosted an exceptional 6.51% and closed at $12.10. On May/13 SRRA collapsed a chilling -6.81%.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally.

Should I buy SRRA stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Sierra Oncology stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Sierra Oncology stock a buy?

Banks and financial institutions post stock ratings everyday. Unfortunately, we couldn't detect any rating for SRRA stock for the last 30 days.

SRRA stock analysis

Daily outlook

Sierra Oncology shares boosted 6.51% to $12.10 today.

Sierra Oncology boosted an exceptional 6.51% and closed at $12.10.

SRRA stock chart (daily)

Weekly outlook

Sierra Oncology remained constant a tight 0.25% this week. Late March SRRA plummed a chilling -14.24% in just one week. Late April SRRA boosted a super good 7.13% in just one week.

SRRA stock chart (weekly)

SRRA stock price history

SRRA IPO was on July 16th, 2015 at $1,147.20 per share1. Since then, SRRA stock lost a -98.90%, with a yearly average of -24.70%.

1: Adjusted price after possible price splits or reverse-splits.

SRRA stock historical price chart

SRRA stock reached 52-week highs at $62.40, and all-time highs 2015-07-16 with a price of 1350.

SRRA stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' SRRA stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price target for Sierra Oncology stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, Sierra Oncology failed to meet the estimates of the analysts and reported a rough EPS of $-0.19 per share when experts were expecting $-0.21.
SRRA earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/an/an/a
2017-Q2-n/an/an/a
2017-Q3-n/an/an/a
2017-Q42018-02-27-0.2-0.2n/a
2018-Q12018-05-10-0.22-0.19n/a
2018-Q22018-08-09-0.16-0.16n/a
2018-Q32018-11-08-0.18-0.21n/a
2018-Q42019-02-28-0.21-0.19n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In , Sierra Oncology annual sales to million dollars from marked in . When comparing vs , , profit margin (that is, the net income divided by revenues) a to .

SRRA annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter income marked $-14.28 M with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Sierra Oncology sales marked a tight move and stayed constant a nan%. Looking back to recent quarterly results, Sierra Oncology posted 7 negative quarters in a row.
SRRA quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

Sierra Oncology ownership

Reviewing Sierra Oncology ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.

Sierra Oncology shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 3.42% of all shares.

In case of Sierra Oncology stock, 57.14% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SRRA stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Sierra Oncology:

SRRA
Market cap$125.8 M
Total shares10.4 M
Float shares3.3 M
  - Institutional holdings (%)57.1%
  - Insider holdings (%)3.4%
Shares in short selling0.0%

SRRA summary

Friday, May 15th, 2020
Open$11.70
Close$12.10
Day range$11.65 - $12.35
Previous close$11.36
Session gain6.51%
Average true range$1.06
50d mov avg$10.88
100d mov avg$12.54
200d mov avg$13.75
Daily pattern
Weekly pattern lt03a

Sierra Oncology performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked as the bechmarking frame for Sierra Oncology stock.
Stock3m6m12m
SRRASierra Oncology-21.83%26.04%-79.28%

Sierra Oncology competitors

Unfortunately, we could not find any public company that could be defined as Sierra Oncology competitor. This doesn't mean Sierra Oncology does not have any competitor in the market, it's just we could not detected it.